Physician profile
Amanda F Whistler
NPI 1497220594
$1,386.62
in general payments reported to CMS, 2019-2025
18 companies · $13.69 in 2025
The $13.69 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,289 · 2022: $53.74 · 2024: $30.44 · 2025: $13.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $200.16 | 2021 | |
| Lilly USA, LLC | $175.41 | 2021 | |
| Abbvie INC. | $150.67 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $145.33 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $144.37 | 2021 | |
| Novartis Pharmaceuticals Corporation | $127.99 | 2021 | |
| Amgen INC. | $77.19 | 2021-2025 | Repatha |
| Merck Sharp & Dohme LLC | $70.52 | 2021 | |
| Amarin Pharma, INC. | $65.45 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.05 | 2021 | |
| Glaxosmithkline, LLC. | $41.19 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.44 | 2024 | Eliquis |
| Vyera Pharmaceuticals, LLC | $24.92 | 2021 | |
| Phadia US INC. | $21.60 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.64 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $16.34 | 2022 | |
| Gilead Sciences, INC. | $15.32 | 2021 | |
| Eisai INC. | $15.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Whistler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.